<SEC-DOCUMENT>0001140361-21-040205.txt : 20211203
<SEC-HEADER>0001140361-21-040205.hdr.sgml : 20211203
<ACCEPTANCE-DATETIME>20211203120019
ACCESSION NUMBER:		0001140361-21-040205
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211203
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211203
DATE AS OF CHANGE:		20211203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		211469206

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10031464_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:galt="http://galectintherapeutics.com/20211203" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_e9e180e554ca462a84aa4f58506d1cee" contextRef="c20211203to20211203" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_ddb6cad99b784b45b58b69a605cfde32" contextRef="c20211203to20211203">0001133416</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_a07700aa960945079f018185c52df5a2" contextRef="c20211203to20211203">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="galt-20211203.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20211203to20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133416</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman';"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-variant: small-caps; font-weight: bold;">WASHINGTON, D.C. 20549</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: small-caps; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_92e15deaa643409ab865526055fa6b0b" contextRef="c20211203to20211203">8-K</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported):<span style="font-size: 10pt; font-weight: bold;">&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_c730416c1667482a96e1bc7be198b304" contextRef="c20211203to20211203" format="ixt:datemonthdayyearen">December 3, 2021</ix:nonNumeric></span></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
<div><span style="font-family: 'Times New Roman';"><br />
      </span></div>

      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 24pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_4d98c6216ae1488fa51513d27ed6a41d" contextRef="c20211203to20211203">GALECTIN THERAPEUTICS INC.</ix:nonNumeric></span><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</span><span style="font-family: 'Times New Roman';">(Exact name of
        registrant as specified in its charter)</span></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.33%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_00496d0ed3c74ae0a0aef7fbc125596f" contextRef="c20211203to20211203" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.33%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_69f1e457c6194daaa1b5a2d8f18e7231" contextRef="c20211203to20211203">001-31791</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.33%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_04de41ea01e745c69f550b830a229fa2" contextRef="c20211203to20211203">04-3562325</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>
          </td>

    <td style="width: 33.33%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt;">(Commission File Number)</div>
          </td>

    <td style="width: 33.33%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_de445d38ba4949cabedf9daed3f18057" contextRef="c20211203to20211203">4960 PEACHTREE INDUSTRIAL BOULEVARD</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_cb16a7fbe1e44420893143d1b1224f2d" contextRef="c20211203to20211203">STE 240</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_9ecbb082d9e84b20969d39cf7c7b52a8" contextRef="c20211203to20211203">NORCROSS</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_3fb19027151b4ec5b798e7d1f9d333d6" contextRef="c20211203to20211203">GA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_9d2a6357f8994ff79a493f17a80ca2f4" contextRef="c20211203to20211203">30071</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of principal executive office) (zip code)</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code:<span style="font-size: 10pt; font-weight: bold;">&#160;</span><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_633174c584ca47d2972fb3076912752c" contextRef="c20211203to20211203">678</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_ccca3f23f276495e99c48a1151db9e7c" contextRef="c20211203to20211203">620-3186</ix:nonNumeric></span></div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">N/A</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions (see General Instruction A.2. below):</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_f2a85bc8500a44afbef53bb2956a46be" contextRef="c20211203to20211203" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman';">
            <div style="font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_0789afaf906d4979999f9e0cc3526796" contextRef="c20211203to20211203" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman';">
            <div style="font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_2646ef3ed6d742ccaa20e58216f97fef" contextRef="c20211203to20211203" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman';">
            <div style="font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_d03b55b38dbb4ccdbe9e1a6035303201" contextRef="c20211203to20211203" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman';">
            <div style="font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (<span style="font-size: 10pt; color: rgb(0, 0, 0);">&#167;</span>230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (<span style="font-size: 10pt; color: rgb(0, 0, 0);">&#167;</span>240.12b-2 of this chapter).</div>

    <div style="font-family: 'Times New Roman';">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_2940b4b3d09a4234ba8cf626895d21e2" contextRef="c20211203to20211203" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="font-family: 'Times New Roman';">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 17.64%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt; font-weight: bold;">Trading </div>
            <div style="text-align: center; font-size: 10pt; font-weight: bold;">Symbol</div>
          </td>

    <td style="width: 43.13%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt; font-weight: bold;">Name of each exchange on which</div>
            <div style="text-align: center; font-size: 10pt; font-weight: bold;"> registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 39.23%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_f478654f214a4526980607d48d663f84" contextRef="c20211203to20211203">Common Stock $0.001par value per share</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 17.64%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_94853e4ab9724ff68053282a7efdef1e" contextRef="c20211203to20211203">GALT</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 43.13%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_a07700aa960945079f018185c52df5a2">The Nasdaq Capital Market</span><br />
            </div>
          </td>

  </tr>


</table>
    <div> <span style="font-family: 'Times New Roman';"><br />
      </span></div>

    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <!--PROfilePageNumberReset%Num%2%- % - %-->
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECTION 7 &#8211; REGULATION FD</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 7.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman';">
            <div style="font-size: 10pt; font-weight: bold;">Regulation FD Disclosure.</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On<span style="font-size: 10pt; color: rgb(0, 0, 0);"> December 3, 2021</span>, Galectin Therapeutics Inc. (the &#8220;Company) made a presentation after its
      Annual Meeting of Stockholders, a transcript of such is attached hereto as Exhibit 99.1.</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The <span style="font-size: 10pt; color: rgb(0, 0, 0);">information in this report is being furnished pursuant to this Item 7.01 and shall not be deemed
        &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of
        1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report</span>.</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECTION 9 &#8211; FINANCIAL STATEMENTS AND EXHIBITS</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman';">
            <div style="color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 95%; vertical-align: top; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">(d) Exhibits.</div>
            </td>

  </tr>


</table>
    </div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 18%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: justify; font-size: 10pt;"><span style="text-decoration: underline;">Exhibit Number</span></div>
          </td>

    <td style="width: 77%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: left; font-size: 10pt;"><span style="text-decoration: underline;">Description</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 18%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 77%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td style="width: 18%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: justify; font-size: 10pt;"><a href="brhc10031464_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 77%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: justify; font-size: 10pt;">Transcript of presentation, December 3, 2021</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">- 2 - </span></div>

      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf
      by the undersigned hereunto duly authorized.</div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: justify; font-size: 10pt;"><br />
            </div>
          </td>

    <td style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">
            <div style="text-align: justify; font-size: 10pt;">Galectin Therapeutics Inc</div>
          </td>

    <td style="vertical-align: top; width: 26%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 26%; vertical-align: top; font-family: 'Times New Roman';" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman';">
            <div style="text-align: left; font-size: 10pt;">Date: December 3, 2021</div>
          </td>

    <td style="width: 4%; vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman';">
            <div style="text-align: left; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 20%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: left; font-size: 10pt;">/s/ Jack W. Callicutt</div>
          </td>

    <td style="width: 26%; vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: left; font-size: 10pt;">Jack W. Callicutt</div>
          </td>

    <td style="width: 26%; vertical-align: top; font-family: 'Times New Roman';" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">
            <div style="text-align: left; font-size: 10pt;">Chief Financial Officer</div>
          </td>

    <td style="width: 26%; vertical-align: top; font-family: 'Times New Roman';" colspan="1">&#160;</td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="font-family: 'Times New Roman';"><br />
    </div>

    <div style="font-family: 'Times New Roman';">
      <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">- 3 - </span></div>

    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10031464_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: center;">
      <div>
        <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Exhibit 99.1</div>
        <div>&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zb13ee6fe48874c75a49f98ac8b1ecd44" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 100%; text-align: center;"><img src="image00001.jpg"></td>
          </tr>

      </table>
      &#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thanks Kevin.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">And thank you to everyone joining us virtually today.&#160; Unfortunately, we are still unable to hold our annual meeting in person due to Covid-19.&#160; Hopefully,
      this will not be the case next year.&#160; Regardless, I am grateful that you are listening.&#160; Please note that certain statements made today are forward looking in nature.&#160; Please see the forward-looking statements disclaimer attached to the Agenda for
      the Annual Meeting and at the end of the transcript of this presentation.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Before I turn the discussion over to Pol to discuss our drug development programs in more detail, I wanted to share my observations about the Company, since I
      spoke to you last year.&#160; At that time, I mentioned that our mission is to monetize our intellectual property as quickly as possible, by maximizing the use of our limited resources.&#160; Without hesitation that is precisely what we are doing.&#160; While it
      might not be apparent to the market yet, Galectin Therapeutics has been transformed into a new company compared to a year ago today.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Starting with an internal analysis of our goals and contemplating a roadmap for the future of the Company, senior management and I resolved to change our
      corporate culture.&#160; Our Company was perceived as, and frankly had been, an early-stage Company.&#160; However, with our global registration NASH cirrhosis trial, along with the potential to move into a phase 2 oncology program, Galectin Therapeutics in
      our view is better characterized as a late-stage company.&#160; To best align our culture to our reality and to establish an environment to realize our potential value, the strategy was straightforward: expand and strengthen the talent on our team&#8212;whether
      employees or consultants.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We referenced potential industry partners in the videos released on our website over the summer.&#160; I touch on it briefly in my presentation, but in part 2 of
      our panel discussion, we go into more detail.&#160; What I would like investors to understand is partnerships may actually require a similar level of scrutiny as regulatory approval in what I would describe as an accelerated process.&#160; In any due diligence
      discussions, a potential partner will fully evaluate a company&#8217;s pathway to approval.&#160; Before an investment is made, a potential partner not only looks at data but also at every potential regulatory hurdle.&#160; They contemplate every possible scenario
      -- ranging from bioanalytics, to preclinical studies, to CMC, and to the Company&#8217;s potential pipeline, just to name the most obvious.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To make sure we were prepared for these scenarios, we undertook multiple parallel paths over the past year.&#160; Not only did we retain Dr. Ben Carson as a
      strategic consultant, we hired four executives in key leadership positions.&#160; I encourage you to read their bios on our website.&#160; I am confident you will see that we have covered major areas with respect to any due diligence process that will be
      required by potential partners.&#160; Our expanded team possesses large pharma experience including being part of due diligence and registration teams in their past experiences.&#160; Collectively, they possess operational expertise in virtually every aspect
      of drug development.&#160;&#160; As I mentioned in my last press release, we will continue to look for talent to further enhance our ability and add value to the Company.&#160; In all the years I have been associated with Galectin Therapeutics, which is over a
      decade, I do not believe we have ever possessed this level of experience or capability internally.&#160; And in the relatively short time I have worked with our new Team, I am pleased to tell you that the level of professionalism has surpassed even my own
      expectations.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our development programs have continued to progress over the past year.&#160; While Covid19 did present challenges almost everywhere earlier in the year, and
      challenges currently still exist in Europe with NAVIGATE, our global adaptive phase 2b/3 NASH Cirrhosis trial, we are optimistic we will be able to fully enroll our trial.&#160; In addition to hiring an Executive Director of Clinical Operations, we also
      added several staff members in clinical operations comprising a full team of experienced professionals.&#160; This team has worked together in the past on multiple large NASH trials and has built relationships with staff members at many of our
      investigational sites.&#160; As we continue to recruit patients, we plan on adding more support for trial participants and investigator sites.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In July, we released additional top line extension data from an investigator-initiated combination immuno-oncology trial in advanced metastatic melanoma and
      head and neck cancer patients.&#160; As we have mentioned in the past, we were encouraged by the results and at the request of our Chairman, Richard Uihlein, as well as the Board, we have been exploring potential pathways for Company-sponsored cancer
      trials.&#160; We are pleased to announce that we have retained as consultants Dr. Chetan Bettegowda from Johns Hopkins, Dr. Nishant Argawal and Dr. Ari Rosenberg both from University of Chicago Medical Center.&#160; I will let Pol speak in more detail about
      our goals and objectives, but I wanted to give a brief overview of our current strategy.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In my remarks last year, I mentioned that our detailed process would focus on areas where we have knowledge and data in order to develop a roadmap to achieve
      our mission by maximizing our limited resources.&#160; With that goal and our desire to optimize value, in our initial discussions with Dr. Bettegowda we considered the landscape in immuno-oncology.&#160; Those discussions caused us to re-evaluate both patient
      populations included in the phase 1 investigator-initiated trial.&#160; After several discussions and introductions to Dr. Argawal and Dr. Rosenberg, our current strategy is to focus primarily on head and neck cancer patients while continuing discussions
      for other indications conditional on partnership collaboration.&#160; This decision is informed by several factors, including current front-line treatments, current active trials, response rates to available therapies, and potential regulatory pathways.&#160;
      After multiple discussions, we believe that this patient population presents the most direct path forward to achieve our mission.&#160; While we still intend on pursuing other oncology indications, at present our internal resources will be directed
      towards the most expedient strategy with the highest medical need. We have already had initial discussions on potential protocols, and we will keep you updated on our progress.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Before I turn the program over to Pol, I wanted to share one more thought with you.&#160; Biotech in general has had a difficult year in 2021.&#160; Although the
      Company has performed well compared to Biotech indices year to date, we were not immune from market pressure.&#160; While there is substantial evidence that galectin-3 plays a role in many disease mechanisms, and there have been numerous scientific papers
      published underscoring that hypothesis, the Company currently has clinical data in hepatology and oncology indications.&#160; Highlighting this fact, I encourage you to read the peer reviewed oncology articles published this year, as well as the six
      presentations that we made at AASLD.&#160; Senior management and the Board are committed to carefully allocating our limited resources to the areas in which the Company is in a leadership position and has the best potential.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On a personal note, my belief in our Company and our technology was only a part of my rationale for my compensation package.&#160; By taking 80% of my compensation
      in stock, I also wanted to invest in the Company directly, preserving limited resources to enable us to achieve our potential.&#160; This is the same position I had previously taken with my Board compensation before I became CEO.&#160; A summary of my
      compensation strategy is listed in a footnote in every Form 4 filed around every pay period and effectively says I am purchasing shares equivalent to 80% of my salary, no matter the share price.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I want to thank our Chairman, Richard Uihlein, for his commitment including his time and multiple investments this year.&#160; Also, I want to thank the entire
      Board for its efforts and, more importantly, for their confidence in me in reshaping our Company.&#160; I am extremely proud of senior management and our entire team.&#160; We will build on our accomplishments from this year by expanding our internal
      capabilities and continuing to advance our programs.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Now I would like to turn the discussion over to Pol to go into more details of our NASH cirrhosis and oncology programs. Pol.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thank you, Joel.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As a quick reminder, NAVIGATE is &#8220;A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating
      the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis.&#8221; For the phase 2b part of the NAVIGATE study, we plan to enroll approximately 315 patients, and, in addition to safety, the main outcome for evaluating
      efficacy is the incidence of esophageal varices after 18 months of treatment. Esophageal varices are evaluated by a central review of recorded endoscopic videos. We will compare the incidence of varices between two belapectin treatment groups and the
      placebo group.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The trial design is very innovative and is a first for the hepatology community. We believe it represents a significant advance for the treatment of NASH
      cirrhosis. As a testimony of this innovation, we were able to present this new study concept at the congress of the American Association for the Study of Liver Diseases, the premier US Hepatology congress, a few weeks ago.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">What is also important to understand is that the target population of NAVIGATE -- patients with NASH cirrhosis who do not have yet decompensated their disease
      but have developed portal hypertension -- is a population who is at risk of developing a clinical event, such as esophageal varices. The development of an esophageal varix is a very concerning event in the life of a cirrhotic patient because this
      varix can bleed and, in that case, the bleeding can immediately become life threatening. Focusing on the prevention of esophageal varices allows us to evaluate a relevant clinical outcome without having to perform liver biopsy, which, now, if you
      closely follow NASH clinical development, is a very controversial and problematic way to evaluate NASH drugs.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">It is also important to understand that esophageal endoscopies, contrary to liver biopsy, is part of the standard clinical surveillance of a cirrhotic
      patient. Hence, NAVIGATE is not only an innovative trial, it is also a very pragmatic clinical trial.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have now initiated NAVIGATE in all countries we originally selected for participation. As we communicated, the process of country initiation and site
      start-up has been impacted by the COVID-19 pandemic, particularly outside of the US. But the last country that was originally planned, namely South Korea, is now on board.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In anticipation of this pandemic impact, we made the decision some months ago to initiate additional countries to be able to balance risks, should this be
      necessary. These additional countries are on the verge of being initiated and will very soon contribute to our global recruitment effort.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">While the pandemic situation remains challenging, we have made good progress with our recruitment campaign. As could be anticipated, for a new design
      targeting a new population, very different from any other NASH studies, sites had to learn what were the best recruitment practices. Thanks to their feedback and the ongoing analysis of our screening and randomized population, we have been able to
      make technical adjustments to the protocol that, we are convinced, will further improve recruitment.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on the feedback we receive from our investigators, there is no question in our mind that the study is considered an important milestone by the medical
      community. NAVIGATE should further trigger the interest of clinical researchers for cirrhosis in general, and NASH cirrhosis in particular, something that is also part of our mission at Galectin Therapeutics. As we previously communicated, our
      objective is now to complete the recruitment of the phase 2b part of the study by the end of June 2022.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Now, turning to the oncology program, we have recently conducted a strategic review of the field with our consultants, particularly the immunotherapy of
      cancer. On one hand, we want to continue to build our program on top of the encouraging clinical data we have produced; on the other hand we have to make sure we are targeting the population that is in the highest need of new treatment. These are two
      necessary conditions to fulfill our objective, which is to provide access to belapectin as quickly as possible, including a registration as the ultimate goal.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This is why, as Joel mentioned, we want to prioritize our internal effort towards the Head and Neck cancer indication. Thanks to the results of our previous
      clinical study, we believe Galectin Therapeutics remains the oncology leader for the clinical translation of the anti-galectin-3 mechanism of action. While we think that the melanoma indication is certainly justified by our positive phase 1 data,
      this field is very competitive, particularly for clinical study recruitment, and we would only venture there with the support of a partner for a phase 2 multicenter study.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Consequently, with the help of our consultants, we are now also developing a phase 2 belapectin protocol for Head and Neck cancer patients and will provide
      further information on our operational plans as quickly as possible.&#160;&#160; I now turn it back to Joel.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thanks Pol.&#160;&#160; Once again thank you all for attending this morning.&#160;&#160; We are looking forward to significant achievements in our development programs in 2022
      and will keep you informed of our progress.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward Looking Statements</div>
    <div>&#160; <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to
      future events or future financial performance, and use words such as &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;could,&#8221; &#8220;expect&#8221; and others. They are based on management&#8217;s current expectations and are subject to factors and uncertainties that could cause actual results to
      differ materially from those described in the statements. These statements include those regarding the hope that Galectin&#8217;s development program for belapectin will lead to the first therapy for the treatment of fatty liver disease with cirrhosis and
      those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements
      include, among others, that trial endpoints required by the FDA may not be achieved; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in
      development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company&#8217;s current clinical trial and any future clinical studies as modified to meet the
      requirements of the FDA may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin&#8217;s
      drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing
      partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs
      may be impacted by its ability to manage costs and finance continuing operations. Global factors such as coronavirus may continue to impact NASH patient populations around the globe and slow trial enrollment and prolong the duration of the trial and
      significantly impact associated costs.&#160; For a discussion of additional factors impacting Galectin&#8217;s business, see the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent filings with the SEC. You should not place
      undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>galt-20211203.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://galectintherapeutics.com/20211203" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:galt="http://galectintherapeutics.com/20211203" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20211203_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20211203_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>galt-20211203_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>galt-20211203_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="galt-20211203.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://galectintherapeutics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  ^ /,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZF>3:P&,Y
M&>M><>+OB_H>AZVNA:9;7FOZ^S;?L&FKO9&[AVZ+COWYK)_:7^($O@?P:D.F
M2^7K&J$P6[]XD'WW^H! 'N:SOV7?!T&C^ H=>N4#ZOK>9WG;EA%D[%R?7[Q]
M<\T ==;^*?B!+;"9OA[9Q9Y$3^($\S'T\K&?;-6M ^)&G7VJOH^L6=WH.N(A
MD^QWX"^:H&2T3@E7'&>#GVKM%4%1CTKA_BYX-@\:>"+ZQ5,:A%&TUE./OQ2@
M$C!Z@-T/UH Z'P;XFLO%WANSUO2UE%E=[S%YJ[6PKE3D?536WFO,?V<6*_!C
MPNF/^64H)],3/7IA- #LTQY-K ;<Y[YH8D=!Q3=H?K]* /&/''Q^M_"FL?V7
M=>$M;2\9]L1NBD$<J[MN]6!8E??%>UJ^Y01WKY7_ &QOW?B/P8%QSY@Y'^VM
M?4ZC"@#TH =FC-1L^. ,GTHW'<!CK0!)FC---("2>* 'YHS4;/@X_2N9^(WB
MV#P;X-U/7)S$S6L1,4;M@2R'A4_$_P!: .JS3/-PV,=_6H;.<SVD,S@*9$5]
MOID9KS3XD3?$1?'/AM?!D4+Z 9%^WDA?[WS;\\[=O3'>@#U3-&:83C))&*;O
M('(Q0!+FC=4>X\8%!(9<B@##\8>+]*\(Z>E[K<KQ6SR")62-G.X@D< >QKF]
M'^+_ (:UJ^%GI U&\G/&V&SD;'U.,"J_QJ\,77BK2=(TRRR#)J*-+)CB*(*^
MYCZ^WN11K6I>%/A%X.CDEC^S6PPD<48#374G_LQ[DG@5#Y^;38[$L/&@I23Y
MWTZ'H\=QOB5]I&X9VG@US'BWQYIWA2%I]7M-4%HOWKFWLWFC7ZE0<?C7S5JG
M[4?B WC#2M#TN"U!^5+AGD<CW*D ?E7I7PI^/FB^,)3I?B"WAT?4G4E2\@-O
M. .1D_=..Q_.K.,UV_:-^'2]=1O/_ *3_"F_\-(?#G_H)7G_ (!2?X5\K_'*
MY\(W7C.XF\"Q.EFP(N&5=L#2YY,0ZA3[\9Z5YOF@#]!_#'QO\$^)M2-AI-]<
MR7"PO.0]JZ (@RQR1Z5MZ9\2O"FINJV>L6[EEE=<[E#+&NZ0C(YVCK]#7QY^
MRD2/C-IN/^>$_7_<-?3FK?"+3-1L])M[B_O&&G-.4VA0SB6X\UP?8\I[@T >
MH:;?6^IZ=:W]C*LUI=1)/#(O1T8!E(^H(HJOX=TZ/1_#^F:9 Q:*RM8K9&88
M)5$"@X'3I10!\A_MK74S?$;1K4N3!'I*RHOHS32AC^(1?RKZ@^%J+_PK+PK@
M #^S+?IQ_P LUKP/]M3PM-)+HGBB&,M#'&;"Y<<[!N+1D^V6<?4BO8/@#KD6
MN?"7P])'(&DMH!93 ?PO'\N#^ !_&@#T-FVY). .YJHNHZ>3E;VU/J?.7_&K
M;(LD9610RL,$'D$5\K_M6^"?#_ASPWH^H^']-@TRYDO&AD^S@H)%VD\CIP1U
MH ^F+>?2[2V6WT^6SC5<[(H74 9.3@#ZFO*_B%K/B[6_B=I/@S0QJ&DZ+)"+
MF_U6U3YRF#\JN00O0#CG)]JQ?V8?!6@R?#_3?$5WIT-QK#SR.MS,-S1A6VC;
MG@<#K]:[;XB_$ZR\*7UIH5C:2ZOXFOB%M]-@8*23T+M_"I/X]Z ,;XB>"[S1
M_!NHZQX8\5>)K;5-+MVO%\[4'GCG"#<0ZMD<@'ICGVK?^ WC:Z\>?#ZWU744
MC6_CE:VG,8PKLN/G [9STKFO'/A;Q#J'P]\0:GXUUV0R1:=<3KI.E?Z/:(PC
M8@.WWY>?4@>Q%5OV/2#\+;G!!_XF$O\ ): .*_;+_P"1E\%?]M/_ $-*^F-:
MU2UT72+S4M1E$-G:0M-+(>RJ,FOF?]LO_D9?!7_;3_T-*]1_:<DN(_@MKWV3
M<&)@#E>NSS4W?AB@#EO .OWGQ2:^USQ#XCFT+0TN&@L=*LKY;5W"]7E8$,>H
MXX&<]JR_%WC*\^$GC32);/Q)/X@\*ZED7%I=72W,EL5*Y*R9R.#D9ZX.<UJ?
MLU>$O"NO_"?3KK4]!TR]O%FFCEEGME=R0YQDD<\$5ZI_PKCP4BG'A310,?\
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MS+FS27;+;RY5B^ P#*V-IY/0=JT+[P[<?VSX$^Q>'TBT_2C*98D9&2V#QE%
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MI+;2IY1"W$>?GCE)VJ0.",UZFD$: [0?Q8FG+&J]!^9S0/F/&OVF/".M>,_
MEAIWART-W>1Z@D[Q[PI">6XSDX[D5\S?\*"^(W_0 /\ W_C_ ,:^^S;QG;D'
MAMP^8]:D"@=!3)/@#_A07Q&_Z !_[_Q_XT?\*"^(W_0 /_?^/_&OO_ HP* /
ME#]G+X6>+O"'Q'CU3Q!I?V6R%K-&9#*K?,P&!@&O1_VA/!FN>+X-%70+9)VM
MWD:3=($P"!CK]*]E:%&;<0<^S$4[RU]*F<%-69MAZTJ%158[H^:/@[\,/%7A
MSQW::EJ]C%#:)%(K,)E8Y*X' KZ3 RM2;%/84H4"E3IJFK(K$XF>)DISW0+]
)T?2BEHJSG/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>brhc10031464_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="galt-20211203.xsd" xlink:type="simple"/>
    <context id="c20211203to20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20211203to20211203"
      id="Fact_e9e180e554ca462a84aa4f58506d1cee">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20211203to20211203"
      id="Fact_ddb6cad99b784b45b58b69a605cfde32">0001133416</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20211203to20211203"
      id="Fact_a07700aa960945079f018185c52df5a2">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20211203to20211203"
      id="Fact_92e15deaa643409ab865526055fa6b0b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20211203to20211203"
      id="Fact_c730416c1667482a96e1bc7be198b304">2021-12-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20211203to20211203"
      id="Fact_4d98c6216ae1488fa51513d27ed6a41d">GALECTIN THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20211203to20211203"
      id="Fact_00496d0ed3c74ae0a0aef7fbc125596f">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20211203to20211203"
      id="Fact_69f1e457c6194daaa1b5a2d8f18e7231">001-31791</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20211203to20211203"
      id="Fact_04de41ea01e745c69f550b830a229fa2">04-3562325</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20211203to20211203"
      id="Fact_de445d38ba4949cabedf9daed3f18057">4960 PEACHTREE INDUSTRIAL BOULEVARD</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20211203to20211203"
      id="Fact_cb16a7fbe1e44420893143d1b1224f2d">STE 240</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20211203to20211203"
      id="Fact_9ecbb082d9e84b20969d39cf7c7b52a8">NORCROSS</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20211203to20211203"
      id="Fact_3fb19027151b4ec5b798e7d1f9d333d6">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20211203to20211203"
      id="Fact_9d2a6357f8994ff79a493f17a80ca2f4">30071</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20211203to20211203"
      id="Fact_633174c584ca47d2972fb3076912752c">678</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20211203to20211203"
      id="Fact_ccca3f23f276495e99c48a1151db9e7c">620-3186</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20211203to20211203"
      id="Fact_f2a85bc8500a44afbef53bb2956a46be">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20211203to20211203"
      id="Fact_0789afaf906d4979999f9e0cc3526796">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20211203to20211203"
      id="Fact_2646ef3ed6d742ccaa20e58216f97fef">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20211203to20211203"
      id="Fact_d03b55b38dbb4ccdbe9e1a6035303201">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20211203to20211203"
      id="Fact_2940b4b3d09a4234ba8cf626895d21e2">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle
      contextRef="c20211203to20211203"
      id="Fact_f478654f214a4526980607d48d663f84">Common Stock $0.001par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20211203to20211203"
      id="Fact_94853e4ab9724ff68053282a7efdef1e">GALT</dei:TradingSymbol>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140013581909512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  03,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GALECTIN THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3562325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4960 PEACHTREE INDUSTRIAL BOULEVARD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">STE 240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">NORCROSS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-3186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001133416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GALT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M> \^>Q\ETWLJ.?]74_P$4$L#!!0    (  E@@U.7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ "6"#4QPX9>H_ 0
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M 5!+ 0(4 Q0    (  E@@U,'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "6"#4]LIO>WM    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ "6"#4YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  )8(-3HCF[<VD$  #\$   &
M        @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ "6"#4Y^@&_"Q @  X@P   T              ( !JPP  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  )8(-3EXJ[',     3 @  "P
M@ &'#P  7W)E;',O+G)E;'-02P$"% ,4    "  )8(-3'#AEZC\!   \ @
M#P              @ %P$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M"6"#4R0>FZ*M    ^ $  !H              ( !W!$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ "6"#4V60>9(9 0  SP,  !,
M             ( !P1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  "Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10031464_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galectintherapeutics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10031464_8k.htm">brhc10031464_8k.htm</File>
    <File>brhc10031464_ex99-1.htm</File>
    <File>galt-20211203.xsd</File>
    <File>galt-20211203_lab.xml</File>
    <File>galt-20211203_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10031464_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10031464_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "galt-20211203_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "galt-20211203_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "galt-20211203.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "galt",
   "nsuri": "http://galectintherapeutics.com/20211203",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10031464_8k.htm",
      "contextRef": "c20211203to20211203",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://galectintherapeutics.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10031464_8k.htm",
      "contextRef": "c20211203to20211203",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://galectintherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-21-040205-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-21-040205-xbrl.zip
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M<2656*:CRY*.J:2:IHLU29,4(AN4Z%B5R!9FW\?6%=LW>FR?Z+=N.E^&W?8
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M%679KLQWUTA(641CM61XMT+=^^O3!OL[S^?\3S\G$Q\N_@M02P,$%     @
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M2Y)>0]IO60FQCZG2V=4_4$L#!!0    (  E@@U/SA"@%@0@  ')8   5
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M>O!"C'7#2+T%AJ_L9;5Z==>=BN]P+*W%%3OBW_Q;-(7Y-^7._@=02P,$%
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M)N7E F<:Y8!?WJ$#^IX.Z'LZH/^>'&"3^DH'] \.^/@.'3#P=,# TP&#]^0
MF]17.F!P<,#PO3C@0GR\9S.ZS>KT+Z-<ZA^C@&M?2>@4Y8^3Z)X/Y-:=47SQ
MKG+/IHP^D?T?:RO5KX"Z+%"" O=!/;53S%#*I!T!N0UHVGG_XEI['3 ASHN
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M+FAT;5!+ 0(4 Q0    (  E@@U.<S$*2DQT  /AA   7              "
M 7D3  !B<FAC,3 P,S$T-C1?97@Y.2TQ+FAT;5!+ 0(4 Q0    (  E@@U/S
MM+9+6P,  )</   1              "  4$Q  !G86QT+3(P,C$Q,C S+GAS
M9%!+ 0(4 Q0    (  E@@U/SA"@%@0@  ')8   5              "  <LT
M  !G86QT+3(P,C$Q,C S7VQA8BYX;6Q02P$"% ,4    "  )8(-3H4.CX>L%
M   '/P  %0              @ %_/0  9V%L="TR,#(Q,3(P,U]P<F4N>&UL
64$L%!@     %  4 2P$  )U#      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
